gdc
FDA Approvals, News & UpdatesLiver CancerNewsworthy

Lenvima a New Option Approved for Initial Treatment of Liver Cancer

Previously approved for thyroid cancer and kidney cancer, the FDA has recently approved Lenvima as the first treatment for patients with liver cancer.
October 2018 Vol 4 No 5

In August 2018, the FDA approved Lenvima (lenvatinib; from Eisai) as the first treatment for patients with unresectable hepatocellular carcinoma, or liver cancer. Lenvima was previously approved for thyroid cancer and for kidney cancer.

This new approval was based on a clinical trial of 954 patients with untreated metastatic or unresectable liver cancer, which showed that those who received Lenvima had on average double the time (7.3 months versus 3.6 months) without disease progression than those who received Nexavar (sorafenib). In addition, the response rate was 41% with Lenvima and 12% with Nexavar. The average overall survival was 13.6 months with Lenvima and 12.3 months with Nexavar.

The most common side effects with Lenvima in the study were similar to side effects reported in other studies.

Share this:

Recommended For You
FDA Approvals, News & UpdatesLymphoma
FDA Approved Breyanzi, Novel Gene Therapy, for Large B-Cell Lymphoma
In February 2021, the FDA approved Breyanzi (lisocabtagene maraleucel; from Juno Therapeutics), a new CAR T-cell therapy, for the treatment of adults with relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic therapy.
FDA Approvals, News & UpdatesFollicular LymphomaLymphoma
FDA Approved Ukoniq, New Targeted Therapy, for Marginal-Zone and Follicular Lymphoma
In February 2021, the FDA approved Ukoniq (umbralisib; from TG Therapeutics), an oral kinase inhibitor, for the treatment of adults with relapsed or refractory marginal-zone lymphoma (MZL) or with relapsed or refractory follicular lymphoma.
FDA Approvals, News & UpdatesFollicular Lymphoma
Yescarta First Gene Therapy Approved for Follicular Lymphoma
In March 2021, the FDA approved a new indication for Yescarta (axicabtagene ciloleucel; from Kite Pharma), a CAR T-cell therapy, for the treatment of patients with relapsed or refractory follicular lymphoma who have received 2 or more lines of systemic therapy.
FDA Approvals, News & UpdatesMultiple Myeloma
FDA Approves Abecma, First CAR T-Cell Therapy for Multiple Myeloma
In March 2021, the FDA approved Abecma (idecabtagene vicleucel; from Bristol Myers Squibb/Bluebird Bio), a BCMA-directed, genetically modified CAR T-cell therapy, for the treatment of adults with multiple myeloma whose disease did not respond to, or returned, after 4 or more lines of therapy.
Last modified: December 20, 2018

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country